FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
3 reports, 2 independent
Updated Wed 00:00
Still developing
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approval enables 60 Degrees Pharmaceuticals to pursue commercial expansion in the U.S.1 source
FDA reviewed NDA and funded babesiosis trial involving 60 Degrees and Mount Sinai.1 source
Keep exploring
The entities involved
Related events
- FDA approval supports NDA submission in Aurora.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- Clinical Trials Arena60 Degrees to commence Phase II babesiosis trial at Mount Sinai 60 Degrees Pharmaceuticals has entered a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the US, choosing